This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nominations Pursuant To Advance Notice Policy

DiagnoCure has also continued to develop robust molecular tests that address unmet clinical needs. This effort contributes management credibility to discussions with potential partners.

Nominations by DiagnoCure in the best interest of shareholders

DiagnoCure's nominees, who are all current directors of the Corporation, control, directly or indirectly, 2,135,846 shares of the Corporation representing approximately 5.0% of all issued and outstanding shares. They present themselves as a team. Consequently, it is likely that individual board members, including Dr. Yves Fradet, will not choose to continue in their roles as directors unless the entire team is re-elected.

"With a recently renewed Board, bringing together diversified outstanding talents and wide‐ranging experience, DiagnoCure is advancing a plan to increase shareholder value. We believe that untimely changes to DiagnoCure's board would send a negative message to our potential partners and to the financial markets," indicated Dr.  Yves Fradet, Chairman of the Board, and President and Chief Medical Officer of the Corporation.

Consequently, DiagnoCure's management and Board of directors maintain their recommendation to vote in favor of their candidates, as indicated in the management proxy circular dated March 11, 2013.

About DiagnoCure's nominees

Dr. Yves Fradet, 62, from Québec, Quebec, Canada, is co-founder of the Corporation and Chairman of the Board of directors of DiagnoCure since January 2010 and President of the Corporation since February 2010. He graduated from Medical School at Université Laval in 1976 and is member of the Royal College of Physicians and Surgeons of Canada since 1981. He has been professor of surgery/urology at Université Laval since 1992. Dr. Fradet studied at the Memorial Sloan-Kettering Cancer Center in New York from 1981 to 1983, where he sub-specialized in urologic oncology. He is a member of several national and international associations including the American Association of Genitourinary Surgeons limited to 75 active members in North America among the leaders of urology. Dr. Fradet received numerous honours during his career including the Lifetime career achievement award from the Canadian Urology Association in 2012 and the Queen Elizabeth Diamond Jubilee Medal from Canadian Medical Association in 2013.

Dr.  Louise Proulx, 62, from Montréal, Quebec, Canada, holds a Ph.D. in physiology from Université Laval and pursued postdoctoral studies at the Karolinska Institute in Stockholm. She has close to 30 years experience in research and science management. From 1977 to 1985, she focused her efforts on prostate and breast cancer at the Centre hospitalier de l'Université Laval. From 1985 to 2001, she took over scientific positions of increasing responsibilities, notably as Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, and Vice President, Therapeutic Product Development at Biochem Pharma. She was later Vice President, Business Development of Genome Québec (2001-2002), Vice Principal Research at McGill University (2002-2004) and Vice President, Product Development at Topigen Pharmaceuticals, Inc. (2004-2006). From December 2006 to March 2009, she was Vice President, Product Development at ViroChem Pharma, Inc. This company was acquired in March 2009 by Vertex Pharmaceuticals, and Dr. Proulx was named Vice President, Research and Development of the Canadian arm. In 2011, she became Vice-President and Site Head until December 2012. Dr. Proulx has been a member of several Boards of directors over her career, and is currently director of the Canada Foundation for Innovation, of Univalor inc., of the Research Institute of the McGill University Health Center (RIMUHC) and of BioQuébec. She is certified ICD.D by the Institute of Corporate Directors.

Mr. Andy Sheldon, 57, from Québec, Quebec, Canada, has been President and Chief Executive Officer of Medicago Inc., a clinical-stage biopharmaceutical company, since August 2003. He has thirty years of experience in the pharmaceutical industry, and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012. Before joining Medicago, Mr. Sheldon was Vice-President, Sales and Marketing of Shire Biologics, where he was responsible for international expansion with European, American and Asian private partnership agreements and was also responsible for distribution, customer service, maintenance and engineering at the Shire facility. From 1998 to 2000, he was Senior Manager of Commercial Operations where he successfully managed the approval of a bladder cancer therapeutic vaccine by the FDA. In 1997 and 1998, he was Marketing Manager for Merial Canada Inc. From 1992 to 1997, he was Director of Canadian Operations with Rhône Mérieux. From 1988 to 1992, he was National Sales Manager for SmithKline Beecham. Mr. Sheldon has a Bachelor's degree in agricultural sciences from Université Laval, Québec City and a Bachelor's of science degree with honors in biological sciences from the University of East Anglia, Norwich, England.

Dr. Jacques Simoneau, 55, from Saint-Bruno-de-Montarville, Quebec, Canada, is President & CEO and director of Gestion Univalor, L.P., a limited partnership responsible for the commercialization and transfer of technologies and innovations created at Université de Montréal, its affiliated schools Polytechnique Montréal (engineering) and HEC Montréal (business), and its hospitals and health research centres. Dr. Simoneau is a corporate director with a comprehensive experience in venture capital and private equity. Prior to joining Univalor, he was Executive Vice President, Investments of the Business Development Bank of Canada (BDC). In that capacity, he was responsible for the venture capital and subordinate financing portfolios. Prior to that, he was President and CEO of Hydro-Québec CapiTech Inc., Senior Vice-President of the Fonds de solidarité FTQ and CEO of Société Innovatech du sud du Québec. He also held executive positions at Advanced Scientific Computing and Alcan. Dr. Simoneau is a director of Transat Inc. A.T., of Azimut Exploration, and of Sustainable Development Technology Canada. He serves on the scientific committee of the Centre québécois de recherche et de développement de l'aluminium and on the University of Montréal's Faculty of Medicine's advisory committee. Dr. Simoneau was a member of the Conseil de la science et de la technologie du Québec from 2004 to 2011, and was also director of three other public companies and 14 private companies between 1995 and now. Jacques Simoneau is a mechanical engineer and holds a M.Sc. from Université Laval and a Ph.D. from Queen's University. He is a member of the Ordre des ingénieurs du Québec, of Professional Engineers Ontario and he is certified ICD.D by the Institute of Corporate Directors.

Dr. Vincent R. Zurawski, 66, from West Chester, Pennsylvania, United States, earned his Ph.D. from Purdue University in 1973 and completed post-doctoral training at the Massachusetts General Hospital and Harvard Medical School. Dr. Zurawski was a pioneer in the biotechnology industry. In 1979, he was one of the founders of Centocor, Inc., where he played a major role in developing and implementing the successful business strategy of the company and the development of all its cancer diagnostic products. In 1992, Dr. Zurawski was founder, President and Chief Executive Officer of Apollon, Inc. and during his six-year tenure at Apollon, he built an operation from the ground up that established itself as a leader in the development of DNA-based vaccines with five Apollon-manufactured products in clinical trials. In 1998, the company was sold to American Home Products (Wyeth Pharmaceuticals), which has since been acquired by Pfizer & Company. Pfizer continues to develop the Apollon DNA-based vaccines. From 1998 to 2000, Dr. Zurawski served as Director for Research Business Development for the University of Pennsylvania, Health System and School of Medicine and in 2000 he was named Chief Executive Officer of Compugen, Inc., the wholly-owned U.S. subsidiary of Compugen, Ltd., a company specializing in the commercialization of bioinformatics software systems. Since leaving Compugen, Inc., Dr. Zurawski has been engaged in a number of start-up biotechnology companies. Following a 3-year tenure as a board member of Hepregen Corporation, he was recently named President and Chief Executive Officer of Hepregen, a leader in the development of micro-liver products. He is also Founding President and Chief Scientific Officer of Varinel, Inc., a pharmaceutical company that specializes in the development of drugs for treatment of diseases of the central nervous system.

None of the proposed directors is, as of the date of this press release or has been within 10 years before March 11, 2013, which is the date of the management proxy circular, a director or an officer of a company that while that person was acting in that capacity or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

In addition, none of the proposed directors has, within the 10 years before the date of the management proxy circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of such proposed director.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs